Who are OnabotulinumtoxinA 145 UNT [Botox]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botox 100 UNT Injection, powder BoNT-A (BOTOX/Vistabel), BOTULINUM TOXIN TYPE B, NAFT500 (adult), NAFT600 (adult), OnabotulinumtoxinA (ONA).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/onabotulinumtoxina-145-unt-botox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

OnabotulinumtoxinA 145 UNT [Botox] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OnabotulinumtoxinA 145 UNT [Botox] (OnabotulinumtoxinA 145 UNT [Botox]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology, Dermatology, Aesthetics.

marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Dermatology, Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

OnabotulinumtoxinA 145 UNT [Botox] (OnabotulinumtoxinA 145 UNT [Botox]) — Beth Israel Deaconess Medical Center. OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OnabotulinumtoxinA 145 UNT [Botox] TARGET	OnabotulinumtoxinA 145 UNT [Botox]	Beth Israel Deaconess Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox 100 UNT Injection	Botox 100 UNT Injection	Brigitte Schürch	marketed	Botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
powder BoNT-A (BOTOX/Vistabel)	powder BoNT-A (BOTOX/Vistabel)	Galderma R&D	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
BOTULINUM TOXIN TYPE B	BOTULINUM TOXIN TYPE B	Eisai Co., Ltd.	marketed	Neurotoxin; botulinum toxin	Synaptobrevin (VAMP)
NAFT500 (adult)	NAFT500 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
NAFT600 (adult)	NAFT600 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
OnabotulinumtoxinA (ONA)	OnabotulinumtoxinA (ONA)	Hexsel Dermatology Clinic	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OnabotulinumtoxinA 145 UNT [Botox] — Competitive Intelligence Brief. https://druglandscape.com/ci/onabotulinumtoxina-145-unt-botox. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab